June 30 (Reuters) – Vistagen Therapeutics said on Tuesday its experimental anxiety disorder drug failed to meet the main goal of a late-stage trial testing its ability to reduce symptoms in adults
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)